enabl
innov
access
health
technolog
remain
key
strategi
combat
infecti
diseas
lowand
middleincom
countri
lmic
howev
gulf
pay
market
endem
diseas
contribut
dearth
r
meet
public
health
need
pharmaceut
industri
view
emerg
economi
potenti
new
market
world
poorest
bottom
billion
resid
middleincom
countriesa
fact
complic
tier
access
arrang
howev
product
develop
partnershipsparticularli
involv
academ
institut
small
firmsfind
commerci
opportun
pursu
even
neglect
diseas
grow
pharmaceut
sector
bric
countri
offer
hope
indigen
base
innov
innov
shape
access
build
block
knowledg
strateg
use
intellectu
properti
innov
financ
meet
public
health
goal
collabor
norm
open
innov
altern
busi
model
doubl
bottom
line
face
resourc
constraint
lmic
pois
develop
new
resourceeffect
model
innov
hold
excit
promis
meet
need
global
health
infecti
diseas
remain
signific
contributor
burden
diseas
lowand
middleincom
countri
lmic
lead
communic
diseas
aid
tuberculosi
malaria
diarrheal
diseas
measl
lower
respiratori
infect
claim
upward
eleven
million
live
countri
year
burden
fall
disproportion
countri
also
vulner
part
popul
notabl
percent
death
respiratori
infect
percent
death
diarrheal
diseas
occur
lmic
diarrhea
pneumonia
measl
malaria
take
mani
live
children
five
similarli
infecti
diseas
like
schistosomiasi
hookworm
malaria
contribut
anemia
worsen
outcom
mother
child
pregnanc
syphili
also
advers
affect
neonat
mortal
diseas
make
substanti
portion
global
diseas
burdenhivaid
tuberculosi
malariaov
percent
death
caus
diseas
also
lmic
toll
infecti
diseas
come
mortal
morbid
lost
work
product
econom
loss
drag
effect
trap
tip
poverti
ill
attain
millennium
develop
goal
mdg
close
entwin
progress
reduc
burden
infecti
diseas
mdg
focus
combat
hivaid
malaria
diseas
step
toward
meet
mdg
reduc
child
mortal
mdg
improv
matern
health
mdg
improv
basic
sanit
sustain
access
safe
drink
water
also
relat
treatment
infecti
diseas
mdg
provid
access
afford
essenti
drug
develop
countri
cooper
pharmaceut
compani
mdg
make
avail
benefit
new
technolog
especi
inform
commun
cooper
privat
sector
align
goal
also
suggest
instrument
mean
accomplish
tripl
therapi
aid
directlyobserv
therapi
tb
oral
rehydr
salt
vaccin
childhood
killer
like
diarrhea
pneumonia
past
decad
wit
signific
advanc
global
health
technolog
introduc
use
resourcelimit
set
current
r
pipelin
global
health
includ
medic
product
variou
stage
develop
nevertheless
unfinish
agenda
requir
technolog
innov
health
technolog
diagnos
prevent
treat
diseas
reduc
risk
diseas
improv
sanit
mitig
health
outcom
exampl
combat
malnutrit
ensur
better
deliveri
intervent
still
mani
technolog
remain
reach
million
might
benefit
lmic
group
annual
health
expenditur
per
capita
us
middleincom
countri
togeth
seen
substanti
rise
per
capita
annual
health
expenditur
around
us
us
health
spend
household
lowincom
countri
overal
remain
much
lower
climb
us
period
us
per
capita
though
price
antiretrovir
arv
therapi
fallen
dramat
percent
past
decad
less
quarter
need
arv
actual
receiv
treatment
leav
least
million
peopl
live
hlv
resid
lowand
middleincom
countri
still
without
treatment
base
preval
data
technolog
also
come
consider
cost
health
system
outofpocket
payment
remain
primari
sourc
cover
cost
medicin
lowand
middleincom
countri
appli
system
think
perspect
might
done
reshap
enabl
environ
innov
health
technolog
meet
twin
goal
innov
access
key
bring
technolog
bench
bedsid
focus
pharmaceut
valu
chain
might
offer
insight
best
ensur
technolog
innov
access
appropri
diseaseendem
countri
deliv
effect
artemisinin
combin
therapi
malaria
provid
case
exampl
sever
intervent
along
valu
chain
shape
avail
afford
treatment
deliv
exist
health
technolog
need
artemisinin
combin
therapi
malaria
afford
medicin
facilitymalaria
amfm
sought
stem
irrat
treatment
approach
malaria
amfm
work
negoti
lower
price
artemisinin
combin
treatment
act
manufactur
subsid
purchas
act
copay
support
intervent
encourag
ration
use
act
sharpli
reduc
retail
price
act
initi
hope
displac
oral
artemisinin
monotherapi
medicin
chloroquin
sulfadoxinepyrimethamin
resist
emerg
unitaid
gate
foundat
dfid
support
pilot
intervent
us
million
global
fund
complement
commit
us
million
toward
support
intervent
scale
act
use
effect
premis
preliminari
find
behind
pilot
illustr
complex
deliv
even
exist
innov
need
earli
find
health
action
intern
price
survey
six
african
countri
show
amfm
price
best
origin
brand
lowestpr
gener
approach
yet
consist
beat
price
irrat
altern
like
chloroquin
sulfadoxinepyrimethamin
less
year
though
six
eight
pilot
countri
met
exceed
benchmark
avail
price
market
share
qualityassur
act
rural
urban
area
effort
tanzania
show
accredit
drug
dispens
outlet
could
complement
upstream
intervent
increas
access
dispens
subsid
artemisinin
combin
therapi
howev
volatil
artemisinin
suppli
upstream
caus
signific
price
fluctuat
price
activ
pharmaceut
ingredi
drug
though
may
offset
entir
greater
demand
artemisinin
expand
amfm
anticip
advent
artemisinin
sourc
microbi
product
late
technolog
may
help
stabil
secur
suppli
critic
drug
act
innov
take
sever
form
diseaseendem
countri
technolog
challeng
may
one
novel
invent
also
local
adapt
exist
technolog
adapt
might
target
local
endem
strain
meningococc
pneumococc
vaccin
introduct
technolog
lmic
lag
health
technolog
might
requir
lyophil
kept
cold
chain
storag
perhap
soon
stabil
silk
film
transport
tropic
climat
perhap
crucial
technolog
adapt
meet
resourc
constraint
diseaseendem
countri
train
health
personnel
health
care
infrastructur
may
want
might
requir
cours
encourag
innov
diseaseendem
countri
necessarili
engag
diseaseendem
countri
process
innov
health
technolog
set
look
industrysupport
phase
clinic
trial
conduct
twenti
largest
usbas
pharmaceut
compani
third
studi
conduct
sole
outsid
unit
state
major
studi
site
resid
outsid
unit
state
much
global
clinic
research
lowand
middleincom
countri
shift
involv
upstream
conduct
clinic
trial
diseaseendem
set
work
bench
scienc
would
also
mark
progress
build
innov
capac
diseaseendem
countri
consid
access
sever
relat
dimensionseach
correspond
differ
part
valu
chain
deliv
technologiesmatt
primari
focu
technolog
innov
therapeut
access
refer
whether
diagnost
drug
vaccin
research
develop
pipelin
financi
structur
access
issu
also
play
import
role
enabl
diffus
technolog
failur
deliv
exist
technolog
like
aid
treatment
oral
rehydr
salt
children
diarrhea
illustr
challeng
financi
structur
access
barrier
respect
therapeut
access
refer
well
r
pipelin
work
financi
access
market
structur
access
deliveri
system
bridg
gulf
market
diseas
endem
death
dali
focu
hivaid
tuberculosi
malaria
global
health
landscap
understand
big
three
diseas
account
million
death
per
year
burden
diseas
fall
disproportion
still
lowand
middleincom
countri
remain
signific
pay
market
industri
countri
well
boost
public
fund
diseas
privat
sector
interest
also
correspondingli
greater
survey
r
project
focus
neglect
diseas
bioventur
global
health
found
r
project
aid
tuberculosi
malaria
four
time
number
project
diarrheal
diseas
includ
rotaviru
cholera
typhoid
fever
shigellosi
enterotoxigen
e
coli
pneumococc
diseas
contrast
diseas
poverti
specif
variou
caus
diarrheal
diseas
pneumococc
infect
claim
million
death
year
number
project
tell
full
stori
stateoftheart
technic
feasibl
next
step
vari
diseas
still
differ
provok
reflect
prioriti
set
tradit
distinct
among
type
diseas
endem
north
south
sizabl
pay
market
north
type
ii
diseas
also
endem
global
disproportion
develop
countri
aid
tuberculosi
type
iii
diseas
endem
develop
countri
depend
size
potenti
pay
market
diseas
distinct
may
help
bound
like
contribut
interest
privat
sector
area
pharmaceut
discoveri
r
pay
market
market
failur
result
bridg
gulf
public
sector
invest
play
import
role
drive
innov
gfinder
survey
found
percent
research
fund
back
neglect
diseas
research
project
origin
highincom
countri
nearli
percent
funder
moni
come
unit
state
publicli
fund
product
develop
partnership
concentr
mission
around
unifi
diseas
technolog
focu
altern
approach
span
cluster
diseas
rais
prospect
share
common
technolog
platform
market
emerg
economi
caught
attent
global
pharmaceut
industri
one
hand
industri
eye
grow
middl
upper
class
emerg
economi
potenti
pay
custom
hand
million
bottom
billion
world
live
middleincom
countri
sharp
contrast
two
decad
ago
percent
poorest
poor
live
lowincom
countri
poor
peopl
live
countri
india
pakistan
indonesia
nigeria
graduat
lowto
middleincom
statu
implic
pharmaceut
innov
access
exampl
establish
tier
scheme
give
preferenti
access
licens
technolog
product
price
tension
made
firm
reluct
offer
break
middleincom
countri
reflect
challeng
medicin
patent
pool
face
recruit
compani
licens
voluntarili
hivaid
drug
gener
product
part
fixeddos
combin
similarli
anchor
glaxosmithklineiniti
pool
open
innov
tropic
neglect
diseas
wipo
search
consortium
effort
pool
build
block
knowledg
licens
royaltyfre
work
neglect
diseas
place
limit
geograph
coverag
least
develop
countri
start
condit
underscor
differ
circumst
face
emerg
economi
develop
countri
stark
realiti
less
quarter
biomed
research
public
less
third
clinic
trial
africa
even
relat
diseas
compris
nearli
percent
burden
diseas
contin
studi
found
research
institut
product
publish
journal
articl
file
patent
concentr
countri
africa
notabl
south
africa
nigeria
egypt
examin
pattern
collabor
biomed
public
threequart
journal
articl
coauthor
collabor
percent
engag
institut
one
african
countri
preponder
major
articl
involv
collabor
europ
unit
state
pattern
collabor
part
motiv
format
african
network
drug
diagnost
innov
focu
intraafrican
coordin
collabor
r
mobil
public
privat
sector
resourc
product
develop
partnership
pdp
step
address
market
failur
bring
forward
treatment
neglect
diseas
studi
neglect
diseas
project
end
tell
interest
stori
half
project
conduct
multin
firm
invari
profitno
loss
basi
project
half
conduct
commerci
basi
smallscal
entiti
small
medium
enterpris
develop
countri
firm
academ
research
institut
arguabl
group
view
opportun
cost
quit
differ
multin
corpor
may
import
insight
target
incent
compani
help
overcom
market
failur
survey
product
develop
engag
drug
vaccin
r
neglect
diseas
suggest
howev
percent
project
involv
pdp
major
go
forward
without
pdp
partner
includ
strong
involv
academ
institut
particularli
studi
neglect
tropic
diseas
less
percent
biotechnolog
compani
global
particip
neglect
diseas
r
still
come
firm
thirteen
twenti
largest
pharmaceut
compani
involv
project
multin
drug
firm
also
begun
shift
pattern
r
recent
boost
approv
new
drug
target
orphan
diseas
respect
orphan
diseas
neglect
diseas
may
two
side
coin
valu
face
small
market
orphan
diseas
small
number
patient
treatment
may
command
high
price
industri
countri
neglect
diseas
million
patient
hope
low
cost
treatment
per
episod
face
loom
cliff
patent
expir
firm
might
also
see
opportun
cost
smaller
market
differ
past
emerg
economi
may
play
increasingli
strateg
role
space
alreadi
india
china
make
signific
invest
domest
r
effort
among
bric
countri
brazil
russia
india
china
south
africa
foreign
assist
develop
countri
risen
near
doubledigit
rate
brazil
health
signific
compon
countri
foreign
assist
budget
brazil
contribut
approxim
us
million
paho
pledg
us
million
global
allianc
vaccin
immun
twentyyear
period
brazil
also
provid
us
million
unitaid
may
brazil
enact
law
donat
us
unitaid
per
intern
flight
contribut
estim
grow
us
million
commit
annual
brazil
also
initi
publicpriv
partnership
transfer
arv
product
technolog
mozambiqu
togeth
govern
mozambiqu
vale
foundat
philanthrop
arm
brazilian
mine
firm
oper
mozambiqu
brazil
institut
technolog
pharmaco
farmanguinho
provid
us
million
help
build
arv
manufactur
plant
oper
plant
produc
five
arv
drug
pharmaceut
includ
pain
reliev
drug
high
blood
pressur
anoth
exampl
southsouth
technolog
transfer
farmanguinho
indian
drug
manufactur
cipla
also
partner
drug
neglect
diseas
initi
dndi
product
develop
partnership
bring
market
new
fixeddos
artemisininbas
combin
treatment
asmq
first
act
threeyear
shelf
life
tropic
climat
farmanguinho
cipla
agre
manufactur
provid
asmq
public
sector
develop
countri
cost
target
price
us
per
full
adult
treatment
innov
neglect
diseas
often
view
less
exemplar
emul
except
pharmaceut
biotechnolog
firm
contribut
neglect
diseas
project
might
argu
translat
new
model
r
collabor
broader
generaliz
lesson
might
deriv
commerci
viabl
therapeut
area
percept
valu
market
lmic
consid
small
diseas
typic
classifi
type
ii
iii
threequart
global
expenditur
pharmaceut
spent
percent
world
popul
live
highincom
countri
howev
patent
cliff
face
multin
pharmaceut
firm
burden
noncommunic
diseas
requir
treatment
lowand
middleincom
countri
avail
public
sector
fund
philanthrop
capit
grow
footprint
indigen
innov
pharmaceut
sector
emerg
economi
might
prompt
rethink
view
spur
initi
struggl
afford
medicin
treat
hivaid
decadelong
polici
processbegin
commiss
intellectu
properti
innov
public
health
continu
world
health
assembl
adopt
global
strategi
plan
action
public
health
innov
intellectu
properti
lead
recent
releas
recommend
consult
expert
work
group
research
develop
financ
coordin
sought
reshap
way
health
technolog
come
market
resourcelimit
set
sever
develop
may
shape
nurtur
direct
approach
innov
emerg
develop
countri
take
import
element
enabl
environ
includ
access
build
block
knowledg
strateg
use
intellectu
properti
innov
financ
meet
public
health
goal
collabor
norm
open
innov
altern
busi
model
doubl
bottom
line
access
build
block
knowledg
key
innov
technolog
transfer
journal
subscript
cost
pose
barrier
access
latest
develop
research
respons
support
health
internetwork
access
research
initi
hinari
work
publish
hinari
provid
tier
access
journal
articl
lowand
middleincom
countri
approach
imperfect
bric
countri
indonesia
thailand
middleincom
countri
inelig
discount
subscript
arrang
despit
sizabl
poor
popul
underresourc
research
institut
countri
voluntari
agreement
provid
workaround
solut
improv
access
research
literatur
past
decad
wit
shortfal
suppli
influenza
vaccin
meet
pandem
heighten
concern
spread
emerg
infecti
diseas
like
sar
avian
flu
wish
last
queue
vaccin
treatment
develop
countri
sought
assur
global
influenza
surveil
respons
system
gisr
share
viru
sampl
would
result
vaccin
industri
countri
also
afford
access
technolog
set
well
pandem
influenza
prepared
framework
lay
standard
materi
transfer
agreement
system
benefit
share
contribut
pharmaceut
manufactur
public
health
research
hortatori
measur
encourag
member
state
urg
manufactur
set
asid
vaccin
influenza
strain
pandem
potenti
stockpil
use
develop
countri
engag
technolog
transfer
effort
make
vaccin
antivir
avail
tier
price
arrang
whether
measur
suffic
event
pandem
sure
test
year
ahead
anticip
need
scale
technolog
provid
seed
grant
manufactur
lowand
middleincom
countri
establish
enhanc
capac
produc
pandem
influenza
vaccin
netherland
vaccin
institut
enlist
provid
train
also
support
influenza
vaccin
technolog
platform
hub
facilit
transfer
technolog
countri
build
upon
robust
transfer
monoval
pilot
process
eggbas
inactiv
whole
viru
influenza
vaccin
product
next
step
plan
work
technolog
platform
technolog
platform
might
potenti
develop
diagnost
therapeut
area
acceler
innov
strateg
manag
intellectu
properti
right
central
secur
access
build
block
knowledg
even
publicli
fund
patent
invent
may
easili
access
research
use
diseaseendem
countri
may
even
less
incent
share
invent
proprietari
privat
fund
howev
especi
neglect
diseas
space
tier
pool
arrang
afford
greater
access
need
research
input
tier
preferenti
discount
even
royaltyfre
access
research
input
provid
often
bound
field
use
geographi
aid
drug
mani
vaccin
tier
price
arrang
offer
price
break
resourcelimit
countri
upstream
mani
neglect
diseas
project
benefit
tier
licens
arrang
wherebi
access
compound
otherwis
inaccess
due
proprietari
natur
provid
r
pathway
repurpos
exist
drug
shorten
consider
access
coupl
preclin
even
clinic
data
compound
pool
arrang
transact
cost
bring
togeth
need
input
research
lower
crosslicens
enabl
vari
degre
result
access
form
success
patchwork
ad
hoc
tier
pool
arrang
emerg
polici
instrument
place
ensur
broader
access
research
input
collabor
medicin
malaria
ventur
glaxosmithklin
releas
chemic
structur
assay
data
compound
activ
malaria
parasit
plasmodium
falciparum
exampl
deposit
pool
european
bioinformat
institut
chembl
databas
us
nih
pubchem
databas
provid
wide
access
creativ
common
licens
work
dedic
public
domain
waiver
copyright
tier
pool
often
work
tandem
medicin
patent
pool
pool
open
innov
neglect
tropic
diseas
wipo
search
consortium
repres
pool
arrang
differ
tier
access
condit
input
pool
work
aggreg
research
input
upstream
r
pipelin
other
recruit
patent
drug
downstream
r
pipelin
exampl
medicin
patent
pool
mission
secur
voluntari
licens
pharmaceut
compani
hivaid
drug
might
use
new
fixeddos
combin
pediatr
formul
gener
licens
combin
meant
stir
greater
competit
therebi
innov
afford
treatment
negoti
licens
limit
field
geographi
proven
challeng
date
licens
compani
aid
medicin
gilead
licens
restrict
manufactur
india
extend
access
result
product
wider
rang
countri
though
still
exclud
sever
middleincom
countri
previou
arrang
open
access
initi
funder
set
norm
support
share
knowledg
also
lower
risk
cross
valley
death
preclin
clinic
test
nih
recent
launch
nation
center
advanc
translat
scienc
ncat
creat
catalyz
gener
innov
method
technolog
might
bring
diagnost
therapeut
firstinhuman
trial
ncat
provid
spectrum
intramur
contract
servic
enabl
small
firm
academ
research
institut
secur
need
preclin
support
funder
also
invest
philanthrop
capit
way
ensur
afford
access
exchang
nondilut
cash
biotechnolog
startup
compani
gate
foundat
support
univers
california
berkeley
extend
coexclus
licens
microbi
synthesi
artemisinin
key
antimalari
drug
amyri
biotechnolog
institut
one
world
health
univers
made
licens
royaltyfre
malaria
indic
exchang
amyri
biotechnolog
commit
produc
artemisinin
profit
treat
malaria
develop
world
amyri
return
also
receiv
substanti
philanthrop
capit
support
us
million
gate
foundat
enabl
amyri
develop
proof
concept
microbi
synthesi
process
also
dual
market
applic
synthes
biofuel
establish
collabor
norm
open
innov
deep
root
public
sector
fund
scienc
wellcom
trust
us
nation
institut
health
nih
engag
lead
center
involv
human
genom
project
agre
bermuda
rule
wherebi
investig
pledg
deposit
gene
sequenc
everi
base
pair
within
hour
complet
genbank
intent
encourag
share
data
also
prevent
unnecessari
patent
defens
publish
nih
also
issu
guidanc
grante
time
releas
share
final
research
data
other
use
minim
unnecessari
encumbr
dissemin
publicli
fund
research
tool
increasingli
pharmaceut
sector
recogn
valu
open
innov
merck
earli
effort
place
express
sequenc
tag
public
domain
corpor
particip
singl
nucleotid
polymorph
consortium
pharmaceut
firm
understood
need
har
idea
outsid
wall
fuel
inhous
r
innov
potenti
applic
open
innov
evid
emerg
infecti
diseas
patent
process
might
outpac
speed
spread
pandem
need
pool
patent
sar
enabl
nonexclus
licens
anticip
potenti
problem
intellectu
properti
hold
develop
diagnost
treatment
ill
howev
sar
epidem
came
went
patent
pool
could
launch
highlight
potenti
valu
open
innov
norm
emerg
diseas
take
step
fledgl
effort
conduct
open
sourc
innov
biomedicin
also
begun
contrast
open
sourc
innov
involv
open
transpar
goal
share
research
collabor
also
prevent
third
parti
acquir
proprietari
right
gener
commun
notabl
india
council
scientif
industri
research
embark
open
sourc
drug
discoveri
osdd
initi
initi
focus
tb
drug
use
webbas
platform
hundr
volunt
network
univers
india
elsewher
collabor
reannot
mycobacterium
tuberculosi
genom
collect
effort
made
possibl
four
month
support
govern
fund
particip
submit
project
open
peer
review
contribut
onlin
effort
system
microattribut
agre
share
work
clickwrap
licens
pursu
convent
path
drug
discoveri
osdd
hope
bring
cost
drug
discoveri
significantli
knowledg
share
construct
collabor
discov
new
chemic
entiti
make
gener
soon
discov
thu
expedit
process
drug
discoveri
mani
neglect
diseas
case
altern
busi
model
clear
demand
side
need
provid
afford
health
technolog
respons
public
health
need
local
context
lowand
middleincom
countri
urgent
suppli
side
high
volum
closer
margin
cost
price
might
match
need
fortun
grow
capac
among
develop
countri
respond
develop
countri
vaccin
manufactur
alreadi
suppli
percent
vaccin
procur
unicef
percent
annual
purchas
volum
antiretrovir
drug
destin
lowand
middleincom
countri
come
indian
gener
manufactur
bridg
suppli
demand
side
need
effici
model
r
innov
like
requir
innov
product
process
describ
variou
name
idea
jugaad
innov
hindi
word
mean
innov
fix
improvis
solut
born
ingenu
clever
resourc
captur
part
spirit
effort
other
appli
descriptor
frugal
innov
howev
import
connot
innov
come
quick
fix
come
sens
thrifti
alon
without
deeper
understand
effect
use
resourc
enabl
condit
innov
must
care
cultiv
nurtur
may
requir
pilot
new
model
collabor
r
effortsshar
resourc
risk
reward
effect
work
constraint
resourcelimit
environ
innov
must
resourceeffect
substandard
effici
use
resourc
reflect
innov
effici
index
score
countri
like
china
india
compar
develop
countri
index
compar
output
innov
constraint
avail
input
innov
countri
measur
china
india
come
first
second
world
perhap
fittingli
suggest
innov
embrac
mahatma
gandhi
tenet
get
less
peopl
best
captur
quot
earth
provid
enough
satisfi
everi
man
need
everi
man
greed
enabl
environ
resourceeffect
innov
like
acceler
health
technolog
infecti
diseas
also
grow
burden
noncommunic
diseas
technolog
like
echocardiographi
clinic
valu
whether
valvular
heart
diseas
trace
rheumat
fever
drug
atherosclerosi
process
technolog
transfer
clinic
trial
platform
train
scientist
also
build
toward
common
purpos
bring
new
health
technolog
bench
bedsid
excit
global
health
worldboth
north
south
much
benefit
new
approach
innov
increas
budget
constraint
industri
countri
might
welcom
costeffect
intervent
born
geniu
innov
resourc
constraint
innov
might
potenti
disrupt
product
target
base
econom
pyramidan
initi
market
margin
competitor
might
migrat
market
displac
establish
technolog
pointofcar
diagnost
afford
drug
vaccin
necess
bring
appropri
afford
health
technolog
may
inde
spark
new
approach
innov
program
global
health
technolog
access
ad
serv
program
director
qre
associ
research
provid
consult
servic
intellectu
properti
manag
product
develop
partnership
drug
neglect
diseas
initi
dndi
author
contribut
ad
led
conceptu
design
behind
overal
organ
manuscript
substant
contribut
collect
inform
data
present
manuscript
ad
also
substanti
wrote
major
manuscript
also
gave
approv
final
submit
version
manuscript
qre
contribut
analysi
research
provid
evid
exampl
given
paper
qre
also
assist
ad
draft
manuscript
author
read
approv
final
manuscript
author
inform
ad
professor
practic
public
polici
global
health
duke
univers
sanford
school
public
polici
also
founder
director
program
global
health
technolog
access
key
focu
area
program
interdisciplinari
work
includ
develop
altern
biopharmaceut
r
model
precompetit
collabor
public
financ
r
evalu
model
innov
access
health
technolog
dr
led
strateg
polici
unit
react
independ
global
network
concert
action
antibiot
resist
advis
themat
refer
group
innov
technolog
platform
infecti
diseas
poverti
work
group
special
programm
research
train
tropic
diseas
serv
member
us
institut
medicin
committe
acceler
rare
diseas
research
orphan
product
develop
author
work
innov
global
health
r
includ
commiss
paper
institut
medicin
share
knowledg
global
health
paper
approach
intellectu
properti
innov
meet
public
health
challeng
aid
global
commiss
hiv
law
year
dr
name
one
robert
wood
johnson
foundat
investig
health
polici
research
previous
dr
associ
director
rockefel
foundat
health
equiti
program
cofound
crossthemat
program
chart
fairer
cours
intellectu
properti
right
shape
foundat
work
access
medicin
polici
develop
countri
launch
multicountri
program
southeast
asia
trade
tobacco
health
focus
enabl
countri
respond
public
health
challeng
tobacco
use
qre
associ
research
program
global
health
technolog
access
help
lead
analys
global
health
polici
research
project
program
